Skip to content

Comparison of Efficacy of Probiotics in Patients with Allergic Rhinitis in the Underground and Surface Environment

Comparison of Efficacy of Probiotics in Patients with Allergic Rhinitis in the Underground and Surface Environment

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR1900020568
Enrollment
Unknown
Registered
2019-01-08
Start date
2019-01-11
Completion date
Unknown
Last updated
2019-01-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Allergic Rhinitis

Interventions

underground control group:placebo
underground probiotics group:probiotics
underground vitamin D group:vitamin D
surface control group:plcebo
surface probiotics group:probiotics
surface vitamin D group:vitamin D

Sponsors

West China Hospital, Sichuan University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 60 Years

Inclusion criteria

Inclusion criteria: (1) the diagnostic criteria for allergic rhinitis should meet the Guidelines for the Diagnosis and Treatment of Allergic Rhinitis (2015, Tianjin); (2) no other nasal and sinus lesions were found in the included patients except allergic rhinitis; (3) aged between 18 and 60 years; (4) the included patients should have normal understanding and communication ability, and sign an informed consent.

Exclusion criteria

Exclusion criteria: 1) patients acute nasal and sinus infections and upper respiratory tract infections occurred in the first two weeks; 2) patients with other systemic diseases, such as heart disease, diabetes, chronic obstructive pulmonary disease, bronchiectasis, nephrotic syndrome, systemic lupus erythematosus, thyroid disease and other endocrine diseases and mental disorders; 3) pregnant or lactating women; 4) patients with malignant tumor history, HIV positive, hepatitis b surface antigen positive, syphilis positive, immune deficiency; 5) patients have used immunosuppressive agents before surgery within two months.

Design outcomes

Primary

MeasureTime frame
Visual Analogue Scale;Rhinoconjunctivitis Quality of Life Questionnaire;Skin Prick Test;Serum cytokines;IgE;regulatory cell;eosinocyte;Serum vitamin D;

Secondary

MeasureTime frame
Nasal Resistance test;Nasal Provocation Test;nasal secretion cytokines;

Countries

China

Contacts

Public ContactZheng Yongbo

West China Hospital, Sichuan University

zheng_yongbo@126.com+86 13982253105

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026